Beigel et al.1111. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19: final report. N Engl J Med. 2020;383(19):1813-26. https://doi.org/10.1056/NEJMoa2007764 https://doi.org/10.1056/NEJMoa2007764...
, 2020 |
To evaluate the clinical effectiveness and safety of using remdesivir in adults hospitalized with COVID-19 |
RCT Multicenter |
The individuals in the study sample came from different countries and were hospitalized with or without supplemental O2, non-invasive MV, and invasive MV. TG: n=538 Intravenous remdesivir: 200 mg on day 1 and 100 mg from day 2 to day 10, or until hospital discharge. PG: n=521 Received a placebo infusion on the same days as the treatment group. |
Mean age TG=58.6 years/PG=59.4 years Mean days of symptoms before randomization TG=9/PG=9 Associated Comorbidities (%): GT=SAH (49.3), Obesity (37.7), DM2 (30.6) PG=SAH (49.9), Obesity (36.2), DM2 (28.7) Therapeutic Management Score *Hospitalization without the need for supplemental O2 (%) TG=12.4/PG=11.5 *Hospitalization with O2(%) TG=41/PG=38.1 *Hospitalization+Non-invasive ventilation (%) TG=18.1/PG=19 *Hospitalization+invasive ventilation (%) TG=23.1/PG=28.2 Mean Recovery Time TG=11 days/PG=15 days *TG randomized within 10 days of symptom onset; had a recovery rate of 1.28. *TG randomized after 10 days of symptoms; had a recovery rate of 1.38. |
Using remdesivir for 10 days in the TG had better results than the placebo when treating hospitalized patients with COVID-19. The results were better in the TG patients who were given remdesivir while receiving supplemental O2. The findings of the study highlight the need for identifying cases in the initial stages of hospital treatment for COVID-19 and begin the antiviral treatment before the disease progresses and requires mechanical ventilation. |
Goldman et al.1212. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med. 2020;383(19):1827-37. https://doi.org/10.1056/NEJMoa2015301 https://doi.org/10.1056/NEJMoa2015301...
, 2020 |
To assess the effectiveness and safety of remdesivir treatment for 5 or 10 days in patients with severe COVID-19 disease |
RCT |
The individuals in the study sample came from different countries and had access to treatment in the clinic. Individuals already using MV for randomization and concomitant drug treatment were excluded. TG5: n=200 Intravenous remdesivir for five days: 200 mg on day 1 and 100 mg from day 2 to day 4. TG10: n=117 Intravenous remdesivir for ten days: 200 mg on day 1 and 100 mg from day 2 to day 9. |
Mean age: TG5=61 years TG10=62 years Mean days of symptoms before randomization: TG5=8/TG10=9 Associated Comorbidities (%): TG5=SAH (50), Dyslipidemia (20), DM2 (24) TG10=SAH (50), Dyslipidemia (25), DM2 (22) Therapeutic Management Score (%) *Not hospitalized TG5=60/TG10=52 *Hospitalization without the need for supplemental O2 TG5=6/TG10=7 *Hospitalization with O2 TG5=10/TG10=7 *Hospitalization+Non-invasive ventilation TG5=4/TG10=5 *Hospitalization+invasive ventilation TG5=8/TG10=17 *Death TG5=16/TG10=21 Recovery Time Day 5 TG5=16/TG10=14 Day 7 TG5=36/TG10=26 Day 11 TG5=58/TG10=49 Day 14 TG5=64/TG10=54 |
In this study, no significant difference in effectiveness was found between using remdesivir for 5 or 10 days. |
Wang et al.1313. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78. https://doi.org/10.1016/S0140-6736(20)31022-9 https://doi.org/10.1016/S0140-6736(20)31...
, 2020 |
To report the results found after using remdesivir in adult patients with severe symptoms of COVID-19 infection |
RCT Multicenter |
The individuals in the study sample came from hospital health services in Wuhan, China. They were admitted in a serious condition due to COVID-19 infection and were 12 days or less from the onset of symptoms. TG: n=155 Intravenous remdesivir: 200 mg on day 1 and 100 mg from day 2 to day 10. PG: n=78 Received a placebo infusion on the same days as the treatment group.
|
Mean age TG=66 years/PG=64 years Associated Comorbidities (%): TG=SAH (46), CAD (9), DM2 (25) PG=SAH (38), CAD (3), DM2 (21) Therapeutic Management Score *Duration of invasive MV (days) TG=7 days/PG=15.5 days *Duration of O2 support (days) TG=19 days/PG=21 days *Hospitalization days TG=25/PG=24 *Hospitalization+invasive ventilation (%) TG=23.1/PG=28.2 *Death (%) Day 7 TG=6/PG=5 Day 14 TG=10/PG=9 Day 28 TG=15/PG=13 Recovery Time TG=21 days/PG=23 days Clinical Improvement Rates (%) Day 7 TG=3/PG=3 Day 14 TG=27/PG=23 Day 28 TG=65/PG=58 |
Using intravenous remdesivir did not significantly improve the time of clinical recovery, mortality, or time to eliminate the virus in patients with severe COVID-19 when compared with the placebo. The study is limited because the lack of hospital beds during the pandemic hindered patients in earlier stages of the symptoms from being admitted. |
Huang et al.1414. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30...
, 2020 |
To present the epidemiological, clinical, laboratory, radiological, treatment, and clinical results of patients with COVID-19 |
Cross-sectional |
41 hospitalized patients were admitted to the study because they were diagnosed with COVID-19. The members were managed with doses of antibiotics (orally and intravenously) and oseltamivir (75 mg orally, twice a day). |
Age (%) 20 (49) of infected patients were between 25 and 49 years old, and 14 (34) were between 50 and 64 years old. Mean age The mean age of patients was 49 years Symptoms at the beginning of the disease Fever (40), cough (3), and myalgia or fatigue (1). Medicines All patients were administered empirical antibiotic treatment and 38 (93%) patients received antiviral therapy (oseltamivir). Hospital discharge (%) On January 22, 2020, 28 (68) of the 41 patients were discharged and six (15) died. The discharge was based on subsided fever for at least 10 days, evidenced radiographic chest improvement, and viral release in upper respiratory tract samples. |
|